-

Bayer to Present Updates on Pharma Growth Strategy and Pipeline Advancements at J.P. Morgan’s 44th Annual Healthcare Conference

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer will participate in the 44th J.P. Morgan Healthcare Conference 2026 taking place from January 12–15, 2026 in San Francisco. Stefan Oelrich, Member of the Board of Management, Bayer AG, and President of Bayer’s Pharmaceuticals Division, will present updates on the company’s pharmaceutical growth strategy and pipeline advancements across its portfolio.

The presentation will take place on Tuesday, January 13, 2026, from 11:15 to 11:55 PST. Investors, analysts, media professionals and members of the life sciences industry are invited to join the live webcast of the presentation via this link. Following the event, the webcast will also be made available with materials related to the presentation on Bayer's website.

About Bayer
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, “Health for all, Hunger for none,” the company’s products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2024, the Group employed around 93,000 people and had sales of 46.6 billion euros. R&D expenses amounted to 6.2 billion euros. For more information, go to www.bayer.com.

Find more information at https://pharma.bayer.com/
Follow us on Facebook: http://www.facebook.com/bayer
Follow us on X: @BayerPharma

Forward-Looking Statements
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports, which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

Contacts

Media Contact:
Elaine Colón
Bayer Media Relations
elaine.colon@bayer.com
+1-732-236-1587

Bayer

GER:BAYN

Release Versions

Contacts

Media Contact:
Elaine Colón
Bayer Media Relations
elaine.colon@bayer.com
+1-732-236-1587

More News From Bayer

Federal Judge Remands Monsanto Class Settlement Case Back to MO State Court

LEVERKUSEN, Germany & ST. LOUIS--(BUSINESS WIRE)--Today, Judge Henry E. Autrey, a federal district court judge in the Eastern District of Missouri, today issued a ruling remanding the class settlement case, King v Monsanto, back to Missouri State Court. Monsanto released the following statement in response to the Court’s decision. “This decision returns jurisdiction over the class settlement to Missouri Circuit Court where the vast majority of pending claims in the Roundup litigation have been...

Bayer Completes Acquisition of Perfuse Therapeutics

BERLIN--(BUSINESS WIRE)--Bayer today announced the completion of the acquisition of Perfuse Therapeutics, Inc. As a result, Perfuse Therapeutics will now be fully integrated into Bayer. As announced previously, Bayer now holds the full rights pertaining to PER-001 intravitreal implant, a first in class, sustained release small molecule endothelin receptor antagonist currently in Phase II clinical development for the treatment of Glaucoma and Diabetic Retinopathy (DR). This acquisition strengthe...

Aleve® Launches its Project DIY Campaign with HGTV Stars Dave & Jenny Marrs to Highlight Hardworking Hobbyists and Long-Lasting Pain Relief

WHIPPANY, N.J.--(BUSINESS WIRE)--Today, Aleve® announced the launch of its Project DIY Campaign, a new DIY-focused marketing initiative under the recently launched Feel Aleve® platform, featuring HGTV stars, Dave and Jenny Marrs. The activation centers around a home transformation project where Dave and Jenny Marrs renovated a family's back porch, taking a non-functioning space and making it into a space the whole family can use and enjoy and bringing to life what it means to Feel Aleve – up to...
Back to Newsroom